Revisiting PPARγ as a new friend of GPR120 in the treatment of metabolic disorders

References

• Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–1808.
   PubMed Web of Science ®Google Scholar
• Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–1830.
   PubMed Web of Science ®Google Scholar
• Oh DY, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010;142:687–698.
   PubMed Web of Science ®Google Scholar
• Oh da Y, Walenta E, Akiyama TE, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med. 2014;20:942–947.
   PubMed Web of Science ®Google Scholar
• Basu A, Jensen MD, McCann F, et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care. 2006;29:510–514.
   PubMed Web of Science ®Google Scholar
• Berria R, Glass L, Mahankali A, et al. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus. Clin Pharmacol Ther. 2007;82:275–281.
   PubMed Web of Science ®Google Scholar
• Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–263.
   PubMed Web of Science ®Google Scholar
• Fonseca V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am J Med. 2003;115(Suppl 8A):42S–48S.
   PubMed Web of Science ®Google Scholar
• Lu M, Sarruf DA, Talukdar S, et al. Brain PPAR-gamma promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med. 2011;17:618–622.
   PubMed Web of Science ®Google Scholar
• Duan SZ, Ivashchenko CY, Russell MW, et al. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptorgamma both induce cardiac hypertrophy in mice. Circ Res. 2005;97:372–379.
   PubMed Web of Science ®Google Scholar
• Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a metaanalysis of randomised clinical trials. Lancet. 2007;370:1129–1136.
   PubMed Web of Science ®Google Scholar
• Son NH, Park TS, Yamashita H, et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest. 2007;117:2791–2801.
   PubMed Web of Science ®Google Scholar
• Bray GA, Smith SR, Banerji MA, et al. Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. Diabetes Obes Metab. 2013;15:931–937.
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Livingstone SJ, Looker HC, et al. Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs. Diabetologia. 2012;55:2929–2937.
   PubMed Web of Science ®Google Scholar
• Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344:e3645.
   PubMed Web of Science ®Google Scholar
• Neumann A, Weill A, Ricordeau P, et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia. 2012;55:1953–1962.
   PubMed Web of Science ®Google Scholar
• Ahmadian M, Suh JM, Hah N, et al. PPARgamma signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557–566.
   PubMed Web of Science ®Google Scholar
• Soccio RE, Chen ER, Lazar MA. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 2014;20:573–591.
   PubMed Web of Science ®Google Scholar
• Wahli W, Michalik L. PPARs at the crossroads of lipid signaling and inflammation. Trends Endocrinol Metab. 2012;23:351–363.
   PubMed Web of Science ®Google Scholar
• Paschoal VA, Walenta E, Talukdar S, et al. Positive reinforcing mechanisms between GPR120 and PPARgamma modulate insulin sensitivity. Cell Metab. 2020;31:1173–1188 e1175.
   PubMed Web of Science ®Google Scholar
• Bell-Parikh LC, Ide T, Lawson JA, et al. Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. J Clin Invest. 2003;112:945–955.
   PubMed Web of Science ®Google Scholar
• Powell WS. 15-Deoxy-delta12,14-PGJ2: endogenous PPARgamma ligand or minor eicosanoid degradation product? J Clin Invest. 2003;112:828–830.
   PubMed Web of Science ®Google Scholar
• Banks AS, McAllister FE, Camporez JP, et al. An ERK/Cdk5 axis controls the diabetogenic actions of PPARgamma. Nature. 2015;517:391–395.
   PubMed Web of Science ®Google Scholar
• Choi JH, Banks AS, Estall JL, et al. Anti-diabetic drugs inhibit obesitylinked phosphorylation of PPARgamma by Cdk5. Nature. 2010;466:451–456.
   PubMed Web of Science ®Google Scholar
• Choi JH, Banks AS, Kamenecka TM, et al. Antidiabetic actions of a non-agonist PPARgamma ligand blocking Cdk5- mediated phosphorylation. Nature. 2011;477:477–481.
   PubMed Web of Science ®Google Scholar